Unicycive Therapeutics
UNCY
79 hedge funds and large institutions have $54.6M invested in Unicycive Therapeutics in 2026 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 7 closing their positions.
400% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 7
126% more call options, than puts
Call options by funds: $8.22M | Put options by funds: $3.63M
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
55% more funds holding
Funds holding: 51 → 79 (+28)
46% more capital inflows, than outflows
Capital inflows: $42.9M | Capital outflows: $29.3M
3.71% less ownership
Funds ownership: 46.09% → 42.39% (-3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.2M |
| 2 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.41M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.73M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
-$9.15M |
| 2 |
Millennium Management
New York
|
-$8.32M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.24M |
| 4 |
Integral Health Asset Management
New York
|
-$1.48M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.3M |
UNCY Hedge Fund Activity: Q2 2026 in Review
79 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q2 2026, worth a combined $54.6M — down 16% from $65.2M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new UNCY positions and 7 closed out — a net gain of 28 holders — while 22 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $10.2M. The largest seller was Vivo Capital, cutting an estimated $9.15M.
- 79 institutional investors held Unicycive Therapeutics (UNCY) as of Q2 2026, up from 51 in Q1 2026.
- Funds reported $54.6M of Unicycive Therapeutics stock for Q2 2026, down 16% quarter-over-quarter.
- 35 funds opened new Unicycive Therapeutics positions in Q2 2026 and 7 closed out, a net change of +28 holders.
- The largest Unicycive Therapeutics buyer in Q2 2026 was BlackRock, an estimated $10.2M added.
- The largest Unicycive Therapeutics seller in Q2 2026 was Vivo Capital, an estimated $9.15M sold.
Based on aggregated 13F filings for Q2 2026.